|
|
|
|
|
|
|
|
The Latest Research, Commentary, and News from Health Affairs
Thursday, October 22, 2020
|
|
|
|
|
|
|
TODAY ON THE BLOG
COVID-19 has upended life for everyone, and has had a profound impact on those who provide and receive health care.
While health care providers from various disciplines united in caring for patients with COVID-19, they learned that the care of these patients was also incredibly lonely and traumatic. Never has it been more important to consider the well-being of providers to help them process trauma, prevent burnout, and provide the best possible care for patients during this challenging time. Provider "heroism" has been a hallmark of the COVID-19 response, but is it a sustainable solution for ensuring that patients get the care they need in a pandemic?
For patients with conditions other than COVID-19, the rapid shift to telemedicine, and the delay of care deemed "non-essential" in light of the
virus caused its own problems, including dangerous diagnostic delays and untreated chronic conditions.
Writing on Health Affairs Blog today, patients and providers present first-person accounts that highlight policy issues raised by the COVID-19 pandemic and response.
And don’t forget: for longer-form personal essays about health care, check out our long-running Narrative Matters series in the journal.
|
|
|
IN THE JOURNAL
CHILDREN'S HEALTH
Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013–18
By Kao-Ping Chua and Rena M. Conti
In this national study of privately insured children, mean annual out-of-pocket spending for orphan drugs increased from $486 in 2013 to $866 in 2018 (78.2 percent). Findings demonstrate that pediatric orphan drug spending is increasingly
burdening payers and families and suggest that payers should better protect families against the prices of orphan drugs by improving benefit design. Read More >>
Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis
By Mary Carmack, Thomas Hwang, and Florence T. Bourgeois
Under the Best Pharmaceuticals for Children Act of 2002 and the Pediatric Research Equity Act of 2003, the Food and Drug Administration (FDA) can request pediatric studies for new drug and biologic indications. Concerns have been raised that delays and noncompliance with study requests contribute to high rates of off-label and potentially unsafe or ineffective medication use in children. Mary Carmack and coauthors used publicly available FDA documents to analyze all indications for new
drugs and biologics approved by the FDA from 2002 through 2018. Read More >>
|
|
|
|
|
A CLOSER LOOK—Pharmacy Benefit
Managers
Many point to pharmacy benefit managers (PBMs) as a cause of high drug prices. The role of PBMs is to lower prices by aggregating health plan customers into large networks for discount negotiation. Reread Michael Carrier’s six-step solution to ensure that PBMs fulfill this role.
|
|
|
|
|
|
|
About Health Affairs
Health Affairs is the leading peer-reviewed journal at the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States
Privacy Policy
|
|
|
|
|
